Peddock Capital Advisors’s Novo Nordisk NVO Stock Holding History

Peddock Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,498	Closed	-$638K	–	164
2025 Q3	$638K	Sell	11,498 -1,197	-9%	-$70.1K	0.14%	96
2025 Q2	$876K	Buy	12,695 +1,280	+11%	+$87.1K	0.2%	83
2025 Q1	$793K	Buy	11,415 +3,445	+43%	+$285K	0.2%	86
2024 Q4	$686K	Sell	7,970 -491	-6%	-$53.1K	0.16%	89
2024 Q3	$1.01M	Buy	8,461 +19	+0.2%	+$2.53K	0.24%	81
2024 Q2	$1.2M	Sell	8,442 -655	-7%	-$86.8K	0.31%	69
2024 Q1	$1.17M	Buy	9,097 +1,410	+18%	+$168K	0.31%	72
2023 Q4	$795K	Buy	7,687 +2,047	+36%	+$202K	0.24%	86
2023 Q3	$513K	Buy	5,640 +674	+14%	+$59.4K	0.17%	94
2023 Q2	$402K	Buy	+4,966	New	+$406K	0.13%	108

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Peddock Capital Advisors's NVO Position: Q4 2025 in Review

Peddock Capital Advisors sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 11,498 shares — an estimated $638K sold.

Peddock Capital Advisors first reported a position in NVO in Q2 2023 and held it in 10 quarters. The position peaked at $1.2M in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Peddock Capital Advisors reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Peddock Capital Advisors sold 11,498 Novo Nordisk shares in Q4 2025, an estimated $638K.
Peddock Capital Advisors first reported a position in Novo Nordisk in Q2 2023 and held it in 10 quarters.
Peddock Capital Advisors's Novo Nordisk position peaked at $1.2M in Q2 2024.
1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Peddock Capital Advisors's 13F filing for Q4 2025, filed 21 Jan 2026.